Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul/Aug;43(4):E159-E171.
doi: 10.1097/SGA.0000000000000523.

Risks and Safety of Advanced Therapies and Biologics in Inflammatory Bowel Disease: A Review for Nurses

Cynthia Morvillo  1   2   3   4   5   6   7 , Katherine Vinci  1   2   3   4   5   6   7 , Lauren Hedenschoug  1   2   3   4   5   6   7 , Leah Mancini  1   2   3   4   5   6   7 , Carrie Mize  1   2   3   4   5   6   7 , Kayce Tugg  1   2   3   4   5   6   7 , Steven Stein  1   2   3   4   5   6   7
Affiliations
Review

Risks and Safety of Advanced Therapies and Biologics in Inflammatory Bowel Disease: A Review for Nurses

Cynthia Morvillo et al. Gastroenterol Nurs. 2020 Jul/Aug.

Abstract

Advanced therapies, including biologics, are a core component of managing inflammatory bowel disease, which is increasing in prevalence. These therapies may offer an improved safety and tolerability profile compared with conventional treatments. However, they can interact with a patient's immune system via different mechanisms. Healthcare providers need to be aware of the possible adverse effects, such as infection and immune-mediated reactions, as well as risk management methods, such as patient screening and vaccination. As central members of the multidisciplinary team, nurses have an important role in educating patients with inflammatory bowel disease on disease course, treatment options, monitoring patient adherence, and response to treatment. This narrative review summarizes key safety considerations for the treatment of inflammatory bowel disease with advanced therapies, including risk of infection and malignancy; immunologic, metabolic, and hematologic complications; and what nurses can do to manage these risks. Special considerations for pediatric, elderly, and pregnant populations are also discussed.

PubMed Disclaimer

References

    1. Aberra F. N., Stettler N., Brensinger C., Lichtenstein G. R., Lewis J. D. (2007). Risk for active tuberculosis in inflammatory bowel disease patients. Clinical Gastroenterology and Hepatology, 5(9), 1070–1075. doi:10.1016/j.cgh.2007.04.007
    1. Allegretti J. R., Barnes E. L., Cameron A. (2015). Are patients with inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasia/cancer? A meta-analysis. Inflammatory Bowel Diseases, 21(5), 1089–1097. doi:10.1097/MIB.0000000000000338
    1. Annese V., Beaugerie L., Egan L., Biancone L., Bolling C., Brandts C.... ECCO (2015). European evidence-based consensus: Inflammatory bowel disease and malignancies. Journal of Crohn's and Colitis, 9(11), 945–965. doi:10.1093/ecco-jcc/jjv141
    1. Appau K. A., Fazio V. W., Shen B., Church J. M., Lashner B., Remzi F., Kiran R. P. (2008). Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. Journal of Gastrointestinal Surgery, 12(10), 1738–1744. doi:10.1007/s11605-008-0646-0
    1. Badat Y., Meissner W. G., Laharie D. (2014). Demyelination in a patient receiving ustekinumab for refractory Crohn's disease. Journal of Crohn's and Colitis, 8(9), 1138–1139. doi:10.1016/j.crohns.2014.02.004

MeSH terms

LinkOut - more resources